MedTrace Logo

A Comparison of the Safety and Comfort of AC-170

NCT01495338 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-09-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and comfort of AC-170 compared to a placebo.

Conditions

  • Normal Ocular Health

Interventions

DRUG

AC-170 0.17%

1 drop in one eye at one timepoint

DRUG

AC-170 0.24% (Formulation 1)

1 drop in one eye at one timepoint

DRUG

AC-170 0.24% (Formulation 2)

1 drop in one eye at one timepoint

DRUG

Olopatadine hydrochloride 0.2%/Tears Naturale II

1 drop in one eye at one timepoint

Sponsors & Collaborators

  • Aciex Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01495338 on ClinicalTrials.gov